Cancers, Vol. 16, Pages 1459: Predictors of Survival, Treatment Modalities, and Clinical Outcomes of Diffuse Large B-Cell Lymphoma in Patients Older Than 70 Years Still an Unmet Medical Need in 2024 Based on Real-World Evidence

Conclusions: In this large and real-life Latin American cohort, we demonstrated that patients with DLBCL, NOS older than 70 years still do not have satisfactory clinical outcomes in 2024, with half of cases not reaching 5 years of life expectancy after diagnosis. Although the conventional R-CHOP offers response and survival advantages over attenuated regimens, its myelotoxicity is not negligible. Therefore, the outcomes reported and the prognostic factors here identified may assist clinicians in the appropriate selection of therapeutic strategies adapted to the risk for old and very old DLBCL patients.

Source: Cancers - April 11, 2024 Category: Cancer & Oncology Authors: Lu ís Alberto de Pádua Covas Lage Rita Novello De Vita Lucas Bassolli de Oliveira Alves Mayara D ’Auria Jacomassi Hebert Fabr ício Culler Cadiele Oliana Reichert F ábio Alessandro de Freitas Vanderson Rocha Sheila Aparecida Coelho Siqueira Renata de Tags: Article Source Type: research